<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE318nnn/GSE318086/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Non-coding RNA profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318086</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>A combinatorial EVs-miRNA signature mediates the anti-tumoral activity of NFAT3- regulated extracellular vesicles in aggressive cancers.</name><description>Aggressive cancers such as triple-negative breast cancer (TNBC) and pancreatic cancer remain difficult to treat because their malignant behavior is driven by complex gene networks rather than single oncogenic targets. Our study identifies a NFAT3 transcription factor-dependent miRNAs signature that suppresses tumor aggressiveness through extracellular vesicles (EVs). Functional analyses demonstrated that a specific combination of fifteen miRNAs (miR-Comb 15) is required to inhibit cancer cell proliferation and invasion across TNBC and pancreatic cancer models, whereas individual miRNA are insufficient to reproduce the full anti-tumoral effect. To enable therapeutic translation, we engineered EVs derived from HEK 293T, a non- tumoral and scalable vesicle source. Using an optimized exogenous pH-gradient loading strategy, miR-Comb 15 was efficiently incorporated into EVs without altering their integrity or intrinsic bioactivity. Among multiple delivery platforms tested, miR-Comb 15 loaded HEK 293T EVs consistently exhibited superior anti-tumoral efficacy both in vitro and in vivo. Together, these findings establish a strong mechanistic link between transcriptional regulation and EVs-mediated RNA delivery and demonstrates that rationally designed RNA combinations delivered by EVs represent a promising therapeutic strategy for aggressive cancers.</description><dates><publication>2026/08/09</publication></dates><accession>GSE318086</accession><cross_references><GSM>GSM9486066</GSM><GSM>GSM9486067</GSM><GSM>GSM9486073</GSM><GSM>GSM9486074</GSM><GSM>GSM9486071</GSM><GSM>GSM9486072</GSM><GSM>GSM9486070</GSM><GSM>GSM9486068</GSM><GSM>GSM9486069</GSM><GPL>18573</GPL><GSE>318086</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>